Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters











Publication year range
1.
Eur J Anaesthesiol ; 25(4): 326-35, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18005471

ABSTRACT

BACKGROUND AND OBJECTIVE: Our aim was to compare a continuous infusion of remifentanil with intermittent boluses of fentanyl as regards the perioperative hormonal stress response and inflammatory activation in coronary artery bypass graft patients under sevoflurane-based anaesthesia. METHODS: In all, 42 patients undergoing coronary artery bypass grafting with cardiopulmonary bypass were prospectively randomized to a fentanyl group (n = 21, total fentanyl dose 2.6 +/- 0.3 mg), or a remifentanil group (n = 21, infusion rate 0.25 microg kg(-1) min(-1)). Haemodynamics, plasma levels of epinephrine, norepinephrine, antidiuretic hormone, adrenocorticotropic hormone, cortisol, complement activation (C3a, C5b-9), interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha were measured at T1: baseline, T2: intubation, T3: sternotomy, T4: 30 min on cardiopulmonary bypass, T5: end of surgery and T6: 8 h postoperatively. Troponin T and creatine kinase-MB were measured postoperatively. RESULTS: Patients in the remifentanil group were extubated significantly earlier than fentanyl patients (240 +/- 182 min vs. 418 +/- 212 min, P = 0.006). Stress hormones 30 min after start of cardiopulmonary bypass showed higher values in the fentanyl group compared to the remifentanil group (antidiuretic hormone (ADH): 39.94 +/- 30.98 vs. 11.7 +/- 22.8 pg mL(-1), P = 0.002; adrenocorticotropic hormone: 111.5 +/- 116.8 vs. 21.81 +/- 24.71 pg mL(-1), P = 0.01; cortisol 185 +/- 86 vs. 131 +/- 82 ng mL(-1), P = 0.04). The interleukins were significantly higher at some perioperative time points in the fentanyl group compared to the remifentanil group (tumour necrosis factor: T5: 3.57 vs. 2.37; IL-6: T5: 4.62 vs. 3.73; and IL-8: T5: 4.43 vs. 2.65 and T6: 2.61 vs. 1.13). However, cardiopulmonary bypass times and aortic cross-clamp times were longer in the fentanyl group, which may to some extent account for the differences. CONCLUSIONS: The perioperative endocrine stress response was attenuated in patients supplemented with continuous remifentanil infusion as compared to intermittent fentanyl.


Subject(s)
Anesthetics, Intravenous/pharmacology , Coronary Artery Bypass/adverse effects , Fentanyl/pharmacology , Piperidines/pharmacology , Stress, Physiological/metabolism , Adrenocorticotropic Hormone/drug effects , Adrenocorticotropic Hormone/metabolism , Aged , Anesthetics, Inhalation/therapeutic use , Anesthetics, Intravenous/administration & dosage , Female , Fentanyl/administration & dosage , Humans , Hydrocortisone/metabolism , Inflammation/etiology , Infusions, Intravenous , Injections, Intravenous , Interleukins/metabolism , Male , Methyl Ethers/therapeutic use , Middle Aged , Piperidines/administration & dosage , Remifentanil , Sevoflurane , Time Factors , Vasopressins/drug effects , Vasopressins/metabolism
2.
Eur J Med Res ; 10(8): 319-24, 2005 Aug 17.
Article in English | MEDLINE | ID: mdl-16131472

ABSTRACT

BACKGROUND: Sepsis is a serious condition, most often occurring as a complication of bacterial infections. The Toll-like receptors (TLR)-2 and TLR-4 have been identified as key molecules in response to Gram-positive and Gram-negative bacteria. This study aimed to assess possible alterations of the surface display of TLR-2 and TLR-4 on monocytes and granulocytes derived from patients with sepsis in comparison with healthy controls. - METHODS: We have utilized flow-cytometry to determine the presence of TLR-2 and TLR-4 on the cell surface at baseline and in response to LPS (40 ng/ml) in vitro. - RESULTS: We found no significant differences of TLR-2 display on monocytes and granulocytes from septic patients compared to controls. Surface display of TLR-4 on monocytes from septic patients at baseline was significantly higher than in healthy controls but there was no further response to LPS, whereas controls showed a significant increase of TLR-4 display on the cell surface after LPS stimulation. In contrast, TLR-4 baseline cell surface display on granulocytes was significantly lower in septic patients than in controls and there was no response to LPS in both groups. - CONCLUSION: Our data suggest a complex relationship between TLR-4 display and bacterial challenge in vivo and in vitro.


Subject(s)
Granulocytes/metabolism , Membrane Glycoproteins/metabolism , Monocytes/metabolism , Receptors, Cell Surface/metabolism , Sepsis/blood , Adult , Aged , Aged, 80 and over , Cells, Cultured , Female , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Gram-Negative Bacterial Infections/metabolism , Gram-Positive Bacterial Infections/metabolism , Humans , Lipopolysaccharides/pharmacology , Male , Middle Aged , Monocytes/drug effects , Toll-Like Receptor 2 , Toll-Like Receptor 4 , Toll-Like Receptors
3.
Intensive Care Med ; 27(10): 1592-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11685299

ABSTRACT

OBJECTIVE: To quantify the incidence and specify the types of medication administration errors from a list of error-prone medications and to determine if patient harm resulted from these errors. DESIGN: An observational evaluation. SETTING: Five intensive care units (ICUs) in the United States. PATIENTS AND PARTICIPANTS: Eight hundred fifty-one patients who were at least 18 years of age and admitted to surgical, medical or mixed ICUs during a 3 month period were included. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: A list of error-prone medications was adapted from the literature and evaluated for medication errors and patient harm. Of 5,744 observations in 851 patients, 187 (3.3%) medication administration errors were detected. the therapeutic classes most commonly associated with errors were vasoactive drugs 61 (32.6%) and sedative/analgesics 48 (25.7%). The most common type of error was wrong infusion rate with 71 (40.1%) errors. Twenty-one errors did not reach the patient and 159 reached the patient but did not result in harm, increased monitoring or intervention. Five errors required increased patient monitoring and two required intervention. None of the errors resulted in patient death. CONCLUSIONS: This multicenter evaluation found fewer medication administration errors than the published literature, possibly due to the varying observational techniques and pharmacist involvement. Lorazepam and wrong infusion rates are associated with errors that occurred frequently, resulted in the greatest potential for harm and were common oversights in the system. These errors should be considered potential areas for betterment in the medication use process to improve patient safety.


Subject(s)
Intensive Care Units/standards , Medication Errors/statistics & numerical data , Adult , Adverse Drug Reaction Reporting Systems , Drug Utilization/standards , Drug Utilization/statistics & numerical data , Hospital Bed Capacity , Hospitals, Teaching/standards , Humans , Incidence , Intensive Care Units/statistics & numerical data , Medication Errors/classification , Medication Errors/prevention & control , Outcome and Process Assessment, Health Care , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/statistics & numerical data , Risk Management , Safety Management , Total Quality Management , United States/epidemiology
4.
Pharmacotherapy ; 21(4): 431-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11310516

ABSTRACT

STUDY OBJECTIVES: To determine the validity and reliability of the Sedation-Agitation scale (SAS) when administered by intensive care unit (ICU) nurses with no experience in its use. DESIGN: Prospective, psychometric evaluation. SETTING: Adult medical-cardiac ICU. PATIENTS: Sixty patients. INTERVENTION: Sedation and agitation were observed simultaneously but independently by nurses and two investigators, and patients were rated with the SAS. The assessment of an experienced clinical nurse specialist was recorded on visual analog scales (VAS) for sedation (VAS-S) and agitation (VAS-A). MEASUREMENTS AND MAIN RESULTS: The SAS scores of ICU staff nurses were compared with VAS scored by the clinical nurse specialist using Pearson correlation coefficient. The SAS correlated well with VAS-S (Spearman's p = -0.77, p<0.001). Neither SAS nor VAS-A was correlated (Spearman's p = 0.05, p>0.5), but there were few observations of agitated patients. The SAS interrater agreement was excellent between the two trained investigators (weighted K = 0.93, p<0.001) and between investigators and staff nurses (weighted K = 0.85 and 0.87, p<0.001 for both). CONCLUSION: The SAS is reliable when administered by staff nurses with no experience with it. Due to the paucity of observations of agitated patients, we were unable to determine its validity for assessing agitation.


Subject(s)
Hypnotics and Sedatives/pharmacology , Nursing Care , Psychomotor Agitation/classification , Female , Humans , Intensive Care Units , Male , Middle Aged , Pain Measurement , Prospective Studies , Psychometrics , Psychomotor Agitation/diagnosis , Reproducibility of Results
5.
Crit Care Med ; 28(11): 3746-50, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11098984

ABSTRACT

OBJECTIVE: The goal of the Task Force on Critical Care Pharmacy Services was to identify and describe the scope of practice that characterizes the critical care pharmacist and critical care pharmacy services. Specifically, the aims were to define the level of clinical practice and specialized skills characterizing the critical care pharmacist as clinician, educator, researcher, and manager; and to recommend fundamental, desirable, and optimal pharmacy services and personnel requirements for the provision of pharmaceutical care to critically ill patients. Hospitals having comprehensive resources as well as those with more limited resources were considered. DATA SOURCES: Consensus opinion of critical care pharmacists from institutions of various sizes providing critical care services within several types of pharmacy practice models was obtained, including community-based and academic practice settings. Existing guidelines and literature describing pharmacy practice and medication use processes were reviewed and adapted for the critical care setting. CONCLUSIONS: By combining the strengths and expertise of critical care pharmacy specialists with existing supporting literature, these recommendations define the level of clinical practice and specialized skills that characterize the critical care pharmacist as clinician, educator, researcher, and manager. This Position Paper recommends fundamental, desirable, and optimal pharmacy services as well as personnel requirements for the provision of pharmaceutical care to critically ill patients.


Subject(s)
Critical Care , Pharmacy Service, Hospital , Humans , Patient Care Team/statistics & numerical data , United States , Workforce
6.
Anal Bioanal Chem ; 353(3-4): 443-6, 1995 Oct.
Article in English | MEDLINE | ID: mdl-15048515

ABSTRACT

The solution of the problem of interchangeability of surface analytical data is gaining increasing importance in multi-method surface analysis. There are various surface analytical instruments in different laboratories on several automation levels. For these instruments, which are controlled by computer systems working with proprietary software under various operating systems, a standardised data format is necessary to allow an exchange of data. Therefore, a toolkit has been developed for the transfer, archiving and editing of surface analytical data in a standardised public domain format. This format contains all available and necessary information on experimental conditions and all parameters specific for a number of analytical techniques such as AES, SAM, XPS, SIMS, STM, AFM and EPMA. Additionally, all data concerning the conditions of sample-preparation and measurement history are included in order to allow a well-founded evaluation of the data and improved reproducibility of the experiment.

7.
Am Heart J ; 116(6 Pt 2): 1806-14, 1988 Dec.
Article in English | MEDLINE | ID: mdl-2904755

ABSTRACT

The antihypertensive efficacy and safety of doxazosin, a selective alpha 1-inhibitor, were compared with nitrendipine. Seventy-two hypertensive patients were entered into the 18-week, double-blind parallel group study, which involved three phases: a 4-week baseline period, a 10-week period in which patients received 1 to 8 mg of doxazosin or 10 and 20 mg of nitrendipine once daily, and a 4-week maintenance period. For all patients, the mean final daily doses were 2.5 mg for doxazosin and 13.9 mg for nitrendipine. In efficacy evaluable patients the percentages of therapy successes (standing diastolic blood pressure less than or equal to 90 mm Hg with greater than or equal to 5 mm Hg reduction or greater than or equal to 10 mm Hg decrease) were comparable for doxazosin (94%) and nitrendipine (91%), as was the proportion in whom blood pressure was "normalized" (standing diastolic blood pressure less than or equal to 90 mm Hg), 91% and 85, respectively. Blood pressures (diastolic and systolic in supine and standing positions) were significantly reduced (p less than 0.05) at all visits in both treatment groups. Ten patients (28%) in each treatment group experienced at least one adverse event. No clinically significant laboratory changes were apparent in either the doxazosin or nitrendipine groups, and no trends were observed with regard to organ systems or correlations with dose or duration of treatments. The investigators' global assessment of efficacy was rated excellent or good for all doxazosin-treated patients and excellent or good for 32 and fair for four in the nitrendipine group.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Nitrendipine/therapeutic use , Prazosin/analogs & derivatives , Adrenergic alpha-Antagonists/adverse effects , Adult , Aged , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Coronary Disease/prevention & control , Double-Blind Method , Doxazosin , Female , Heart Rate/drug effects , Humans , Lipids/blood , Male , Middle Aged , Nitrendipine/adverse effects , Prazosin/adverse effects , Prazosin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL